Accueil・Liste d'Actions・Innoviva Inc

Innoviva Inc

Fermé

SecteurSoins de santé

20.42 -3.13

Acheter Vendre

Résumé

Variation du prix de l'action

24h

Actuel

Min

20.41

Max

20.65

Chiffres clés
By Trading Economics
Revenu	-55M 187M
Ventes	-20M 98M
P/E Moyenne du Secteur	3.318 68.51
BPA	0.47
Marge bénéficiaire	190.415
Employés	159
EBITDA	31M 239M

Recommandations
By TipRanks
Recommandations	Achat Fort
Prévisions sur 12 Mois	+98.29% upside

Dividendes
By Acuity
Prochains Résultats	11 août 2026

Statistiques du Marché
By TradingEconomics
Capitalisation Boursière	-169M 1.5B
Ouverture précédente	23.55
Clôture précédente	20.42

Sentiment de l'Actualité

By Acuity

40%

60%

100 / 340 Classement par Healthcare

Innoviva Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

7 août 2026, 21:01 UTC

Innoviva Inc shares are lower in after-market hours, reflecting a decline since Friday's close and trading near the lower end of their one-month range.

6 août 2026, 19:51 UTC

News

Innoviva Inc shares are higher as the company shifts to a diversified healthcare model, supported by $773 million in investments and positive momentum since Wednesday.

5 août 2026, 21:01 UTC

Innoviva Inc shares are trading higher in after-market hours, recovering from a session low. No specific news was identified to explain the movement.

3 août 2026, 19:46 UTC

News

Innoviva Inc shares are lower today, continuing a downward trend. Analysts from BTIG and HC Wainwright maintain buy ratings with targets of $42.00 and $46.00.

31 juil. 2026, 20:06 UTC

Shares of Innoviva Inc. are trading lower, continuing a downward trend. The stock remains below its 20-day moving average amid no specific news.

30 juil. 2026, 19:02 UTC

Innoviva Inc shares are declining amid market weakness and rising jobless claims. The stock remains near the lower end of its one-month range.

29 juil. 2026, 19:06 UTC

Macro Event

Innoviva Inc shares are lower today as market scrutiny increases following the Federal Reserve's decision to maintain interest rates amid ongoing geopolitical tensions.

28 juil. 2026, 20:03 UTC

Innoviva Inc shares are higher today, continuing an upward trend since Monday. No specific news was identified to explain the price movement.

27 juil. 2026, 19:56 UTC

Innoviva Inc shares are lower today, reflecting broader market trends amid a significant drop in oil prices. No specific company news was identified.

21 juil. 2026, 15:46 UTC

Innoviva Inc shares are higher today, reflecting a broader trend in rising equity indices. The stock remains below its 20-day moving average.

20 juil. 2026, 18:31 UTC

Innoviva Inc shares are lower today, reflecting broader weakness in the Pharmaceuticals sub-sector. The stock has reversed from a recent trend of higher closes.

Comparaison

Variation de prix

Innoviva Inc prévision

Objectif de Prix

By TipRanks

98.29% hausse

Prévisions sur 12 Mois

Moyen 40.67 USD 98.29%

Haut 46 USD

Bas 34 USD

Basé sur 3 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

3 ratings

Achat

Maintien

Vente

Basé sur 3 qui ont noté l'action Microsoft Corp. au cours des 3 derniers mois.

Sentiment

By Acuity

100 / 340Classement par Soins de santé

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

À Propos Innoviva Inc

Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Its development pipeline includes zoliflodacin, a late-stage product candidate, a potential single oral dose cure for the treatment of uncomplicated gonorrhea. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. It has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.